v3.26.3
Segment Reporting - Schedule of Revenue by Major Customers by Reporting Segments (Details) - USD ($)
$ in Thousands
 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Segment Reporting Information [Line Items]        
Collaboration revenue $ 53,044 $ 50,034 $ 234,603 $ 91,280
R&D (2,668) (1,733) (3,644) 11,495
G&A 23,390 8,298 11,345 13,633
Total operating expenses 20,722 6,565 7,701 25,128
(Loss) income from operations 32,322 43,469 226,902 66,152
Interest income 3,252 5,402 9,813 15,074
Sublease income 526 0 0 0
Non-cash interest expense (41,192) (37,667) (79,893) (50,087)
Other (loss) income, net (1) 5,453 5,453 0
Total other income (expense), net (37,415) (26,812) (64,627) (35,013)
(Loss) income before income taxes (5,093) 16,657 162,275 31,139
Benefit (provision) for income taxes 181,451 (83) (772) (158)
Net income (loss) 130,996 $ (77,959) (13,232) (145,231)
Prior to Spin Off        
Segment Reporting Information [Line Items]        
Collaboration revenue     234,603 91,280
R&D     135,970 163,840
G&A     50,737 42,389
Total operating expenses     186,707 206,229
(Loss) income from operations     47,896 (114,949)
Interest income     13,499 19,794
Non-cash interest expense     (79,893) (50,087)
Other (loss) income, net     5,430 14
Total other income (expense), net     (60,964) (30,279)
(Loss) income before income taxes     (13,068) (145,228)
Benefit (provision) for income taxes     (164) (3)
Net income (loss)     (13,232) (145,231)
External | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     85,177 117,967
G&A     17,944 10,033
Rosnilimab | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     42,744 53,422
ANB033 | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     20,427 12,460
ANB032 | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     48 26,084
ANB101 | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     8,138 3,367
Quimilza | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     (2,273) 8,284
Preclinical and other unallocated costs | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     16,093 14,350
Internal | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     50,793 45,873
G&A     32,793 32,356
Biopharma | Prior to Spin Off        
Segment Reporting Information [Line Items]        
Collaboration revenue     0 0
R&D     139,614 152,345
G&A     39,392 28,756
Total operating expenses     179,006 181,101
(Loss) income from operations     (179,006) (181,101)
Interest income     12,942 17,382
Non-cash interest expense     0 0
Other (loss) income, net     (23) 14
Total other income (expense), net     12,919 17,396
(Loss) income before income taxes     (166,087) (163,705)
Benefit (provision) for income taxes     0 0
Net income (loss)     (166,087) (163,705)
Biopharma | External | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     87,450 109,683
G&A     13,932 6,806
Biopharma | Rosnilimab | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     42,744 53,422
Biopharma | ANB033 | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     20,427 12,460
Biopharma | ANB032 | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     48 26,084
Biopharma | ANB101 | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     8,138 3,367
Biopharma | Quimilza | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     0 0
Biopharma | Preclinical and other unallocated costs | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     16,093 14,350
Biopharma | Internal | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     52,164 42,662
G&A     25,460 21,950
Royalty Management        
Segment Reporting Information [Line Items]        
Collaboration revenue 53,044      
R&D (2,668)      
G&A 23,390      
Total operating expenses 20,722      
(Loss) income from operations 32,322      
Interest income 3,252      
Sublease income 526      
Non-cash interest expense (41,192)      
Other (loss) income, net (1)      
Total other income (expense), net (37,415)      
(Loss) income before income taxes (5,093)      
Benefit (provision) for income taxes (181,451)      
Net income (loss) 176,358      
Royalty Management | Prior to Spin Off        
Segment Reporting Information [Line Items]        
Collaboration revenue     234,603 91,280
R&D     (3,644) 11,495
G&A     11,345 13,633
Total operating expenses     7,701 25,128
(Loss) income from operations     226,902 66,152
Interest income     557 2,412
Non-cash interest expense     (79,893) (50,087)
Other (loss) income, net     5,453 0
Total other income (expense), net     (73,883) (47,675)
(Loss) income before income taxes     153,019 18,477
Benefit (provision) for income taxes     (164) (3)
Net income (loss)     152,855 18,474
Royalty Management | External        
Segment Reporting Information [Line Items]        
R&D (2,683)      
G&A 15,161      
Royalty Management | External | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     (2,273) 8,284
G&A     4,012 3,227
Royalty Management | Rosnilimab        
Segment Reporting Information [Line Items]        
R&D (2,897)      
Royalty Management | Rosnilimab | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     0 0
Royalty Management | ANB033 | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     0 0
Royalty Management | ANB032 | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     0 0
Royalty Management | ANB101 | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     0 0
Royalty Management | Quimilza        
Segment Reporting Information [Line Items]        
R&D 21      
Royalty Management | Quimilza | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     (2,273) 8,284
Royalty Management | Preclinical and other unallocated costs        
Segment Reporting Information [Line Items]        
R&D 193      
Royalty Management | Preclinical and other unallocated costs | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     0 0
Royalty Management | Internal        
Segment Reporting Information [Line Items]        
R&D 15      
G&A $ 8,229      
Royalty Management | Internal | Prior to Spin Off        
Segment Reporting Information [Line Items]        
R&D     (1,371) 3,211
G&A     $ 7,333 $ 10,406